Compare Bristol-Myers Squibb Co (BMY) vs Crowdstrike Holdings Inc (CRWD) Price & Performance

Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.

BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.

CrowdStrike (CRWD) trades at $187.91, up 0.39% on the day, with a bullish technical signal and strong support near $185. The stock has delivered three consecutive quarterly EPS beats, with Q2 2026 expected at $0.29. Revenue growth remains robust, rising from $1.5B in 2022 to $4.0B in 2025, though net margins are slightly negative. A recent 4-for-1 stock split on July 2, 2026, has increased accessibility amid heightened investor interest in AI-driven cybersecurity.

Outlook is supported by solid cash flow growth and dominant market positioning, but premium valuations (P/E 765, P/S 37) pose risks if growth decelerates. Analyst consensus is strongly bullish with a $184.39 price target, though competitive pressures and execution challenges remain key watchpoints for sustained upside.